| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Elliott H. Margulies | Q5365658 | ||
| Katherine Stemke-Hale | Q52353554 | ||
| Yardena Samuels | Q55130355 | ||
| Jamie K Teer | Q80095848 | ||
| Jared J Gartner | Q91623672 | ||
| P2093 | author name string | Vijay Walia | |
| Xiaomu Wei | |||
| Jeffrey E Gershenwald | |||
| Praveen F Cherukuri | |||
| Michael A Davies | |||
| Alfredo Molinolo | |||
| Jimmy C Lin | |||
| Todd D Prickett | |||
| Jiji Jiang | |||
| Isabel Cardenas-Navia | |||
| P2860 | cites work | Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | Q27851483 |
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Multiplex amplification of large sets of human exons | Q28253118 | ||
| SIFT: Predicting amino acid changes that affect protein function | Q29547211 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Patterns of somatic mutation in human cancer genomes | Q29547841 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Modelling G-protein-coupled receptors for drug design | Q33766736 | ||
| Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins | Q34202874 | ||
| G-protein-coupled receptors and cancer. | Q34606002 | ||
| Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma | Q34682013 | ||
| Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells | Q37087123 | ||
| G-protein-coupled receptors and melanoma | Q37200841 | ||
| Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma | Q37356835 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. | Q40991782 | ||
| Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 | ||
| Pharmacological characterization of metabotropic glutamate receptor-mediated high-affinity GTPase activity in rat cerebral cortical membranes | Q43264619 | ||
| Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway | Q43461747 | ||
| Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group | Q46619788 | ||
| Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. | Q47756832 | ||
| Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia | Q48250298 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | G protein-coupled receptor | Q38173 |
| P304 | page(s) | 1119-1126 | |
| P577 | publication date | 2011-09-25 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma | |
| P478 | volume | 43 |
| Q49954335 | -The a-arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein-coupled receptor lysosomal sorting and signaling |
| Q33917519 | A highly recurrent RPS27 5'UTR mutation in melanoma |
| Q34253185 | Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis |
| Q33560677 | Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression |
| Q38091649 | Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring |
| Q36021702 | BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration |
| Q28544919 | Clonal architectures and driver mutations in metastatic melanomas |
| Q34420417 | Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma |
| Q34737562 | Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling |
| Q36030770 | Delving into somatic variation in sporadic melanoma |
| Q35828069 | Detecting false-positive signals in exome sequencing |
| Q37626431 | Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells |
| Q37162578 | DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies |
| Q42012553 | ERBB4 mutation analysis: emerging molecular target for melanoma treatment. |
| Q37028299 | Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas |
| Q37576033 | Exploiting the curative potential of adoptive T-cell therapy for cancer |
| Q33845217 | FBXW7 mutations in melanoma and a new therapeutic paradigm |
| Q35705859 | Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing |
| Q36409682 | Functional effects of GRM1 suppression in human melanoma cells |
| Q37659860 | G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. |
| Q62884236 | GPCRs in Cancer: Protease-Activated Receptors, Endocytic Adaptors and Signaling |
| Q34411505 | GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma. |
| Q37406812 | Genetics and epigenetics of melanoma |
| Q36563659 | Genetics of melanoma |
| Q88552258 | Genetics of metastasis: melanoma and other cancers |
| Q34048497 | Glutamate and its receptors in cancer |
| Q37121338 | Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications |
| Q37978409 | Glutamatergic signaling in cellular transformation |
| Q47169465 | Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. |
| Q26861766 | Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis |
| Q42773490 | High-throughput sequencing of the melanoma genome |
| Q33819083 | Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. |
| Q33624972 | Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration |
| Q34619124 | Hypoxia-inducible factors enhance glutamate signaling in cancer cells |
| Q36762520 | Illuminating the activation mechanisms and allosteric properties of metabotropic glutamate receptors |
| Q30528247 | Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12. |
| Q37361741 | Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators |
| Q33880126 | Location, location, location: The relationship of anatomic site, antigen expression, and T-cell infiltration in human melanoma metastases |
| Q33704699 | MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line |
| Q34971850 | Melanoma brain colonization involves the emergence of a brain-adaptive phenotype |
| Q38111220 | Melanoma metastasis: new concepts and evolving paradigms |
| Q38710970 | Melanoma-associated GRM3 variants dysregulate melanosome trafficking and cAMP signaling. |
| Q34083191 | Melanoma: clinical features and genomic insights. |
| Q27024061 | Melanoma: from mutations to medicine |
| Q43090167 | MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways |
| Q30570451 | Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells |
| Q37540105 | Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells |
| Q33769639 | Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor |
| Q33591900 | Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas |
| Q38741884 | Metabotropic glutamate receptors in cancer |
| Q78271812 | Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers |
| Q36170150 | Molecular pathways: dysregulated glutamatergic signaling pathways in cancer |
| Q39519769 | Multicolor FISH with improved sensitivity and specificity in the diagnosis of malignant melanoma. |
| Q88637038 | Multifaceted regulation and functions of YAP/TAZ in tumors (Review) |
| Q24298571 | Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP |
| Q42180596 | Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer |
| Q102141804 | Mutational drivers of cancer cell migration and invasion |
| Q39007737 | Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma |
| Q26853582 | New developments in dermatological oncogenetics |
| Q34450728 | Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma |
| Q59137905 | Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo |
| Q26865736 | Pathways and therapeutic targets in melanoma |
| Q38907413 | Patient-derived tumor xenograft models for melanoma drug discovery |
| Q98475181 | Prediction of drug response in multilayer networks based on fusion of multiomics data |
| Q26744512 | Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection |
| Q38833742 | Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways |
| Q37274872 | Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma |
| Q38700311 | Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3. |
| Q39318208 | Regulation of mGluR1 expression in human melanocytes and melanoma cells |
| Q24294906 | Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling |
| Q92786732 | SMARC-B1 deficient sinonasal carcinoma metastasis to the brain with next generation sequencing data: a case report of perineural invasion progressing to leptomeningeal invasion |
| Q37243181 | SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis |
| Q37990969 | Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma |
| Q49386947 | Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing |
| Q38087215 | The Hippo pathway and human cancer. |
| Q38083640 | The Hippo pathway: regulators and regulations |
| Q30410176 | The Hippo signaling pathway in stem cell biology and cancer |
| Q38532696 | The current management of brain metastasis in melanoma: a focus on riluzole |
| Q33799070 | The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. |
| Q38756275 | The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies |
| Q42081827 | The miR-487b-3p/GRM3/TGFβ signaling axis is an important regulator of colon cancer tumorigenesis |
| Q36833326 | Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma |
| Q34213994 | What are we learning from the cancer genome? |
| Q39060449 | Whole-genome landscapes of major melanoma subtypes. |
| Q52312423 | [The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?] |
Search more.